PL3145508T3 - Nanocząstki klewidypiny i ich kompozycje farmaceutyczne - Google Patents

Nanocząstki klewidypiny i ich kompozycje farmaceutyczne

Info

Publication number
PL3145508T3
PL3145508T3 PL15795707.7T PL15795707T PL3145508T3 PL 3145508 T3 PL3145508 T3 PL 3145508T3 PL 15795707 T PL15795707 T PL 15795707T PL 3145508 T3 PL3145508 T3 PL 3145508T3
Authority
PL
Poland
Prior art keywords
clevidipine
nanoparticles
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL15795707.7T
Other languages
English (en)
Inventor
Rajeshwar Motheram
Sr. David C. HANLEY
Akif Emre TÜRELI
Monika KANTER
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL3145508T3 publication Critical patent/PL3145508T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
PL15795707.7T 2014-05-19 2015-05-19 Nanocząstki klewidypiny i ich kompozycje farmaceutyczne PL3145508T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462000119P 2014-05-19 2014-05-19
PCT/US2015/031470 WO2015179334A1 (en) 2014-05-19 2015-05-19 Clevidipine nanoparticles and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
PL3145508T3 true PL3145508T3 (pl) 2023-10-23

Family

ID=54554604

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15795707.7T PL3145508T3 (pl) 2014-05-19 2015-05-19 Nanocząstki klewidypiny i ich kompozycje farmaceutyczne

Country Status (10)

Country Link
US (2) US11737989B2 (pl)
EP (1) EP3145508B1 (pl)
KR (1) KR102380701B1 (pl)
CN (2) CN106456617A (pl)
CA (1) CA2947486C (pl)
ES (1) ES2950154T3 (pl)
MX (1) MX385243B (pl)
PL (1) PL3145508T3 (pl)
RU (1) RU2759673C2 (pl)
WO (1) WO2015179334A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105796490B (zh) * 2016-04-01 2019-12-10 广东药科大学 一种含氨基酸的尼莫地平注射液组合物及其制备方法
CN105796494B (zh) * 2016-04-01 2019-10-11 广东药科大学 一种含氨基酸的尼莫地平亚微乳注射液及其制备方法
CN107281104B (zh) * 2017-05-27 2021-02-02 济南康和医药科技有限公司 一种丁酸氯维地平磷脂复合物脂质体及其制备方法
EP3804703A1 (de) * 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung eines nanopartikulären wirkstoffs
EP3884930A1 (en) 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting
EP4734991A1 (en) * 2023-05-28 2026-05-06 Precise Biopharma Pvt Ltd A room temperature stable aqueous solution for injection of clevidipine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453523A (en) * 1993-06-16 1995-09-26 Emulsion Technology, Inc. Process for obtaining highly purified phosphatidylcholine
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
JP2009536162A (ja) * 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
CA3108961C (en) 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
US8679344B2 (en) * 2008-12-17 2014-03-25 Cerion Technology, Inc. Process for solvent shifting a nanoparticle dispersion
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
PL2550092T3 (pl) * 2010-03-22 2019-01-31 Instillo Gmbh Sposób wytwarzania mikro- lub nanocząstek
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
EP2526926A1 (de) 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
KR101708538B1 (ko) 2011-08-26 2017-02-20 욱크하르트 리미티드 심혈관 질환의 치료 방법
US20150246137A1 (en) 2012-09-27 2015-09-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
CN110840890A (zh) 2012-10-26 2020-02-28 凯西制药公司 用于在心力衰竭中控制血压和减轻呼吸困难的方法
CN103479577A (zh) * 2013-09-30 2014-01-01 山东大学 含有丁酸氯维地平的脂质纳米混悬剂及其冻干制剂

Also Published As

Publication number Publication date
US11737989B2 (en) 2023-08-29
KR20170032886A (ko) 2017-03-23
EP3145508A1 (en) 2017-03-29
CA2947486C (en) 2023-09-26
CN114668740A (zh) 2022-06-28
US20230145206A1 (en) 2023-05-11
ES2950154T3 (es) 2023-10-05
EP3145508C0 (en) 2023-07-05
US12383507B2 (en) 2025-08-12
MX2016015208A (es) 2017-03-23
CA2947486A1 (en) 2015-11-26
RU2759673C2 (ru) 2021-11-16
US20170087093A1 (en) 2017-03-30
RU2016149538A (ru) 2018-06-20
EP3145508A4 (en) 2018-01-24
CN106456617A (zh) 2017-02-22
MX385243B (es) 2025-03-14
KR102380701B1 (ko) 2022-03-31
RU2016149538A3 (pl) 2019-01-17
BR112016027104A2 (pt) 2018-07-10
WO2015179334A1 (en) 2015-11-26
EP3145508B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
IL258931A (en) Therapeutic compounds and methods
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3529248T3 (da) Farmaceutiske sammensætninger
SI3426348T1 (sl) Derivat 3-dezoksi in njegovi farmacevtski sestavki
DK3199161T3 (da) Farmaceutisk præparat
EP3316685A4 (en) Lyophilized Pharmaceutical Compositions
PL3194421T3 (pl) Związki cytotoksyczne i przeciwmitotyczne oraz sposoby ich wykorzystania
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
ZA201703398B (en) Pharmaceutical composition and methods
ZA201607919B (en) Dipicolylamine derivatives and their pharmaceutical uses
EP3145508A4 (en) Clevidipine nanoparticles and pharmaceutical compositions thereof
EP3349788A4 (en) Antimalarial Compositions and Methods
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
PT3302483T (pt) Composições farmacêuticas e seu uso
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf
SI3236952T1 (sl) Farmacevtski sestavek v obliki tablet
DK3166960T3 (da) Lav-substituerede polymyxiner og sammensætninger deraf
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
DK3240529T3 (da) Stabile farmaceutiske sammensætninger omfattende micafungin
DK3089740T3 (da) Farmaceutisk sammensætning
EP3423041A4 (en) PHARMACEUTICAL COMPOSITIONS
EP3528818A4 (en) PHARMACEUTICAL COMPOSITIONS